Secondary Logo

Journal Logo

Microvillous Atrophy: Atypical Presentations

Perry, Ariane*,†,‡; Bensallah, Hayet*,†,‡; Martinez-Vinson, Christine; Berrebi, Dominique*,†,‡; Arbeille, Brigitte§; Salomon, Julie||,¶; Goulet, Olivier||,¶; Marinier, Evelyne; Drunat, Séverine; Samson-Bouma, Marie-Elisabeth¶,#; Gérard, Bénédicte; Hugot, Jean-Pierre*,†,‡

Journal of Pediatric Gastroenterology and Nutrition: December 2014 - Volume 59 - Issue 6 - p 779–785
doi: 10.1097/MPG.0000000000000526
Original Articles: Gastroenterology
Free
SDC

Objectives: Microvillous inclusion disease (MVID) is a cause of intractable diarrhea in infancy. In its classic form, the disease is characterized by a severe persistent watery diarrhea starting within the first days of life. Parenteral nutrition and small bowel transplantation are the only known treatments for the affected children. Histologically, periodic acid-Schiff (PAS) staining shows accumulation of periodic acid-Schiff–positive staining material along the apical pole of enterocytes, whereas transmission electron microscopy exhibits microvillus inclusion bodies within the cytoplasm of enterocytes with rarefied and shortened microvilli and secretory granules. The objective of this work was to explore clinical, morphological, and genetic findings in cases of MVID with unusual presentations.

Methods: Clinical, histological, and genetic findings are reported for 8 cases of MVID with atypical presentation.

Results: The diarrhea started after several months in 3 cases. It was usually less abundant and 3 patients were weaned off parenteral nutrition. None required intestinal transplantation. Three patients experienced malformations, dysmorphy, sensory disabilities, and severe mental retardation. One had a hydrocephaly. Three patients had a cholestasis with low γ-glutamyl transferase levels. Light microscopy showed histological abnormalities consistent with MVID in all of the cases, but the lesions were sometimes focal or delayed. Transmission electron microscopy retrieved some criteria of MVID in 4 patients. Finally, 6 patients were homozygotes or compound heterozygotes for MYO5B mutations.

Conclusions: This study extends the spectrum of MVID to less severe clinical presentations.

Supplemental Digital Content is available in the text

*Université Paris-Diderot-Sorbonne Paris Cité, UMR 1149

Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré

INSERM, UMR1149, Paris

§Department of Electron Microscopy, Université François Rabelais, Tours

||Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades

Université Paris Descartes-Sorbonne Paris Cité

#Université Paris-Diderot, UMR 698, CHU X. Bichat, Paris, France.

Address correspondence and reprint requests to Professor Jean-Pierre Hugot, Service des Maladies Digestives et Respiratoires de l’Enfant, Hôpital Robert Debré, 48 Bd Sérurier, 75019 Paris, France (e-mail: jean-pierre.hugot@rdb.aphp.fr).

Received 30 July, 2014

Accepted 30 July, 2014

Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal's Web site (www.jpgn.org).

This study was supported by Assistance Publique-Hôpitaux de Paris, INSERM and Université Paris-Diderot.

Drs Perry, Bensallah, Gérard, and Hugot contributed equally to the article.

The authors report no conflicts of interest.

Microvillous inclusion disease (MVID) represents 5% to 15% of intractable diarrhea (1–3). MVID was described for the first time by Davidson et al (4). Gestation is most often unremarkable (5–8). The diarrhea usually occurs within the first days of life or less often during the second month of life (9). MVID is characterized by a profuse, secretory, watery, severe diarrhea (up to 150 mL · kg−1 · day−1). The diarrhea persists all along the life, even under total parenteral nutrition (10). Some authors reported MVID-associated abnormalities including cardiac malformations, facial dysmorphia, transient neuronal dysplasia, aganglionic megacolon, Down syndrome, intrahepatic cholestasis, or hypochondroplasia (5,11–16).

Several treatments have been unsuccessfully tested including corticosteroids (12), loperamide (12,17), cromoglycate disodique, cimetidine (17), urogastrone/epidermal growth factor (18,19), and somatostatin (12,20). The only curative treatment is small bowel transplantation, often combined with liver transplantation (15,21,22). When transplanted, only 54% of the patients were weaned off parenteral nutrition (15). Two spontaneous healings have been reported in the literature (11,23).

The criterion standard for diagnosis is a combined histological analysis with light and transmission electron microscopy (TEM). Light microscopic examination of duodenal biopsies shows various degrees of villous atrophy, without local inflammation or crypt hyperplasia (10,12,17). Periodic acid-Schiff (PAS) staining shows decreased reactivity of the brush border and accumulation of PAS-positive staining material along the apical pole of enterocytes. This abnormal staining pattern is pathognomonic of the disease. Vacuolated epithelial cells can be observed (5,11,12,24). These alterations may also affect the colon (10) or the gastric mucosa (25). Immunostaining techniques directed against CD10 or CEA lead to similar results as PAS staining (24,26,27).

TEM shows microvillus inclusion bodies within the cytoplasm, often in the vicinity of lysosomes (28). Microvilli are rarefied, shortened, widened, clubbed, or fused. Microvilli are sometimes observed on the lateral membrane (4,9,12,17,28). These abnormalities mainly affect the mature enterocytes. Additional cell abnormalities include heterogeneous vesicles in microvilli-denuded areas and abundant secretory granules (10,28,29). All of these changes can also be found to a lesser extent in the colonic epithelium (17). In summary, MIVD is characterized by the association of loss of microvilli, microvillous inclusion, and secretory granules.

A genetic cause has been suspected (20,30), and Müller et al (31) found that MYO5B is the main MVID gene. This large-sized gene contains 40 exons and encodes for the 5b myosin motor protein, which is involved in membrane vesicle trafficking. Since the “princeps” article, mutations have been reported in most patients, suggesting low gene heterogeneity (32–34). Patients are usually mutated homozygotes or compound heterozygotes, confirming the recessive mode of inheritance. Myosin5b interacts with rab11a and Rab8a, and this interaction is essential for proper addressing of subapical vesicles and thus proper functioning of polarized cells (37). Thus, the main physiopathological hypothesis for MVID is a defect of exocytosis (29,35,36).

The aim of this study was to provide a clinical, histological, and genetic description of 8 new patients with MVID who were characterized by atypical presentations.

Back to Top | Article Outline

METHODS

Patients

The 8 patients were recruited at Hôpital Robert Debré (n = 7) and Hôpital Necker-Enfants-Malades (n = 1), Assistance Publique-Hôpitaux de Paris, France. Their characteristics are summarized in Table 1. Parents of all of the included patients signed an informed consent.

TABLE 1

TABLE 1

Back to Top | Article Outline

Histological Analyses

Duodenal biopsies were fixed in formalin, embedded in paraffin, and stained by PAS. Immunohistochemistry was done according to standard protocols (mouse monoclonal antibody anti-CD10 ready to use, clone 56C6; Leica Biosystems, Wetzlar, Germany) using the BOND-MAX automat (Leica Biosystems). For TEM, biopsies were fixed in 2.5% glutaraldeyde, washed in cacodylate buffer (0.1 mol/L) (patients 1 and 2) or phosphate buffer (patients 3–8), postfixed in 1% or 2% osmic acid in the same buffer solution, dehydrated in graded alcohols, and finally embedded in an epon mixture. Thin sections were obtained with the UCT Leica ultramicrotome, submitted to a double impregnation of uranyl acetate and lead citrate and then examined with a TEM JEOL 1010 or 1011 kV (Tokyo, Japan) with a camera Gatan ES 1000W Erlangshen (Pleasanton, CA).

Back to Top | Article Outline

Mutation Screening

DNAs were extracted from peripheral blood samples using standard methods. The MYO5B coding regions and splice sites were PCR amplified and directly sequenced using the dye terminator technique. Each sequence was examined manually and mutations were confirmed by a second round of sequences on both strains.

Back to Top | Article Outline

RESULTS

Patient 1 was born at 36 weeks of gestation in a meconium liquor from 2 nonconsanguineous Italian parents. Her birth weight was 2950 g. A severe watery diarrhea started on the second day of life and parenteral nutrition was quickly started. Stool output was up to 1500 mL/day when she was 21 months old. Fluid and electrolyte requirements were high, up to 220 mL · kg−1 · day−1, when she was 4 years old. Her clinical course was marked by adverse effects of parenteral nutrition including nephrocalcinosis, cholestasis, venous thrombosis, and osteoporosis. In addition to her diarrheal disease, she experienced transient humoral immunodeficiency, a dysmorphic syndrome (badly hemmed ears, chest bell, hypertelorism, left single palmar crease), an interstitial lung syndrome, severe failure to thrive (height −5 SD, weight −3 SD), and severe mental retardation. Because of these associated disorders, she was not proposed for small bowel transplantation. At present, she is 19 years old and receives a parenteral nutrition (80 mL · kg−1 · day−1, 12/24 hours every day).

At the age of 3 months, PAS staining revealed typical MVID abnormalities confined to the enterocytes of the surface epithelium and, to a lesser degree, to crypt epithelium (Fig. 1A and Supplementary Fig. 1A, http://links.lww.com/MPG/A360). Mild chorionic edema, normal intraepithelial lymphocyte counts, and frequent mitoses within the crypts were also noted. TEM showed images compatible with MVID. Two mutations were found on exons 19 and 24 (c2259-2262dup and c3163-3165dup) (Fig. 2). The first mutation was in the motor part of the protein. The second mutation (also found in patients 7 and 8) affects the part of the protein that interacts with rab proteins.

FIGURE 1

FIGURE 1

FIGURE 2

FIGURE 2

Patients 2 and 3 are 2 siblings from nonconsanguineous Moroccan parents. They have a sister who is affected by an agenesis of the corpus callosum. Patient 2 was born at term, after an unremarkable gestation, weighing 3290 g. Profuse secretory diarrhea began on the seventh day of life, with ionic disorders and severe dehydration. Parenteral nutrition was immediately started. At present, he is 2 years old and receives parenteral nutrition (110 mL · kg−1 · day−1, 12/24 hours, 7/7 days).

His brother was born at term (birth weight 3570 g) after a gestation marked by a hydramnios and an echogenic bowel at 34 weeks of gestation. Diarrhea began more insidiously and led to malnutrition and ionic disorders only at 6 weeks of life. He is now 1 year old and receives parenteral nutrition daily (110 mL · kg−1 · day−1). The 2 siblings developed an intrahepatic cholestasis with low γ-glutamyl transferase (GGT). Liver biopsies showed centrolobular cholestasis without fibrosis or ductular proliferation.

Histological features of the 2 siblings were similar. At the age of 2 months, duodenum biopsies (Fig. 1B and C, and Supplementary Fig. 1B and C, http://links.lww.com/MPG/A360) revealed a severe villous atrophy in duodenum, accumulation of PAS-staining material at the apex of enterocytes from the surface epithelium and the upper part of the crypts. A mild inflammatory infiltrate of the lamina propria with no increase in intraepithelial lymphocytes and an increased number of mitoses within the crypts was noted. TEM showed heterogeneous lesions of the brush border. Microvilli were shortened (<0.5 μm) and disoriented. No microvillous inclusions were seen but many secretory granules and autophagic vacuoles (Fig. 3A and B). Two MYO5B mutations were found in both siblings in exon 10 (c1222A>T) and 13 (c1582C>T). They lead to amino acid substitutions within the motor part of the protein.

FIGURE 3

FIGURE 3

Patient 4 had a heavy medically charged family history: Berger disease in his father, severe deafness in his mother, and epilepsy in 2 brothers and 1 aunt. One of his brothers died in infancy owing to a similar disease (intestinal failure, facial dysmorphy, retinitis pigmentosa, severe epilepsy, cortical atrophy, mental retardation, and failure to thrive). There was no consanguinity in the family. He was born at term, after an unremarkable gestation, weighting 3360 g. Diarrhea began on the fifth day of life, with severe dehydration and parenteral nutrition requirement (160 mL · kg−1 · day−1). He also experienced hypothalamic hamartoma, sensorial deficiencies (blindness, optical atrophy, nystagmus, unilateral deafness), and severe mental retardation. At present, he is 12 years old and receives parenteral nutrition (65 mL · kg−1 · day−1 every day). He has mild growth retardation (size at −2 SD) and nephrocalcinosis.

MVID was diagnosed on the first duodenal biopsy when he was 22 days old (Fig. 1D and E and Supplementary Figs. 1D and E, http://links.lww.com/MPG/A360). Microscopic observations revealed mild partial villous atrophy. PAS-positive material accumulated at the luminal pole of upper crypt enterocytes whereas surface enterocytes were less affected. CD10—which is normally expressed at the surface of the brush border—also accumulated in the cytoplasm of the enterocytes. There was a mild inflammatory infiltrate within the lamina propria, but no increase in intraepithelial lymphocytes. Colonic biopsies were normal. TEM showed rare microvilli and vacuolization of the cytoplasm. We failed to detect MYO5B mutations (30–33).

Patient 5 was born at 40 weeks of gestation from nonconsanguineous French parents after a pregnancy marked by an intrauterine failure to thrive. He weighed 2380 g. Diarrhea began in the neonatal period in the context of a Staphylococcus aureus and an Escherichia coli K1 sepsis and severe ionic disorders. Parenteral nutrition was quickly started but could be stopped at 4 months and replaced by enteral nutrition. He presented with cholestasis with low GGT and pruritus, which were only partially improved by ursodesoxycolic acid supplementation. Liver biopsy showed mild intrahepatocyte cholestasis without biliary paucity. He had a polymalformative syndrome with facial dysmorphy, blindness (right anophthalmia, iris coloboma, left cataract, optic nerve atrophy), dolichocephaly, laryngeal palsy, deafness, brainstem hypoplasia, and mental retardation. A high-resolution karyotype was normal. Otherwise, he experienced cow's-milk–protein allergy and gastroesophagal reflux disease. At present, he is 13 years old and has a gastrostomy for nocturnal enteral nutrition (60 mL · kg−1 · day−1). He has growth retardation (height −3 SD).

Patient 5 underwent 3 duodenal biopsies showing discrete partial villous atrophy. PAS staining showed focal accumulation at the luminal pole of the enterocytes of the low villous region without inflammatory infiltrate or increased intraepithelial lymphocyte count (Fig. 1F–G and Supplementary Fig. 1F–H, http://links.lww.com/MPG/A360). TEM showed rare and isolated microvilli, with filamentous core rootlets under the terminal web, possible microvillous inclusions, vacuolization of the cytoplasm, and electron-dense vesicles (Fig. 3C and Supplementary Fig. 3, http://links.lww.com/MPG/A362). No MYO5B mutations were found.

Patient 6 was born premature at 31 weeks of gestation (weight 1645 g) from Israeli nonconsanguineous parents. Diarrhea began later, at 14 months of life, characterized by significant steatorrhea (23 g/day when he was 11 years old, 7–14 g/day when he was 14 years old). Parenteral nutrition was started only when he was 3 years old (approximately 60 mL/kg, 6/7 days). He also experienced a neonatal hydrocephaly that was treated surgically. He had normal neurological development. At present, he is 24 years old. At his last visit, when he was 20 years old, he needed parenteral nutrition 4 days/week. He had normal growth.

The diagnosis of MVID was made when he was 4 years old. Standard histology showed mild villous atrophy. Some surface enterocytes were vacuolated and a mild inflammatory infiltrate within the lamina propria was noted. PAS staining showed a focal accumulation pattern in the crypt enterocytes. The last biopsy, when he was 19 years old, showed the same abnormalities (Fig. 1H and Supplementary Fig. 2A and B, http://links.lww.com/MPG/A361). At TEM examination, microvilli were rare and shortened. There were possible microvillous inclusions and lots of secretory granules. Two MYO5B mutations were found. The first one (c656G>A) was located on the sixth exon and was already described in a Turkish patient and the second one was located on the 31st exon (c4028T>C). The mutations affect the motor part and the rab binding domain of the protein.

Patients 7 and 8 are offsprings of French nonconsanguineous parents. Diarrhea began when they were 5 months old, insidiously, with high steatorrhea levels (between 7 and 12 g/day), but low sodium excretion (15 mmol/L for the girl). Parenteral nutrition was started at 8 months for the boy (patient 7) and at 18 months for his younger sister (patient 8). After a few months, it moved for enteral nutrition and then for normal feeding. At the beginning, gluten intolerance was suspected: gluten antibodies were negative for the boy, whereas antigliadin immunoglobulin G levels were elevated for the girl. The boy is now 28 years old and the girl is 11 years old.

For patient 7, until 4 years of age, duodenal biopsies showed total or subtotal villous atrophy with crypt hyperplasia and mild inflammatory infiltrate; however, when he was 18 years old, a duodenal biopsy revealed almost normal villi but a focal PAS-positive pattern, mostly on the apical pole of surface enterocytes. The number of intraepithelial lymphocytes was at the upper limit of normal. TEM showed rare microvilli abnormalities, some electron-dense vesicles, and a mild degree of cellular sickness. For patient 8, the diagnosis was made at 18 months. Focal accumulation of PAS-positive material at the luminal pole of surface and crypt enterocytes was seen. There was only a mild villous atrophy. Histological data improved at 4 years of age, with an almost normal villous relief but the persistence of the abnormal PAS-staining pattern (Fig. 1I and Supplementary Fig. 2C and D). TEM analyses were done earlier for patient 8, when she still had digestive symptoms, and revealed rarefied microvilli, possible microvillous inclusions and electron-dense vesicles (Fig. 3D). Genetic screening found the same 2 mutations in the 2 children. One in the 14th exon (C1347delC) led to a truncated protein. The other one, located on the 24th exon (c3163-3165dup), was also found in patient 1.

Back to Top | Article Outline

DISCUSSION

In summary, all 8 reported patients were characterized by a typical abnormal PAS staining on light microscopy, which made us discuss the diagnosis of MVID. All of them exhibited atypical clinical presentations, but 4 exhibited 1 or more TEM diagnostic hallmarks proposed by Davidson et al (4), including loss of microvilli, microvillus inclusions, and secretory granules. Finally, 6 patients, corresponding to 4 distinct pedigrees, were mutated for MYO5B.

Gestations were unremarkable, except for patient 3. In fact, only 4 cases from the literature had antenatal symptoms consisting of hydramnios or echogenic bowel. Among these 4 cases, 2 mothers had a strict follow-up because of health problems, whereas the third baby had a neuronal intestinal dysplasia with bowel dilatation (5–8). Antenatal echography therefore seems to have a limited role for prenatal diagnostic here and in the literature.

Three patients experienced malformations. All of them had dysmorphy and severe mental retardation. To our knowledge, there are only a few patients described in the literature with malformations (11–13), and none with sensory defects. Only 2 patients with no MYO5B mutations had the most severe malformations, suggesting another genetic cause of their disease. Three patients were small, with height values under −2 SD despite nutritional assistance and sometimes despite a treatment with growth hormone. These data suggest that in some cases MVID may be a component of a more complete syndrome.

In the reported cases, digestive symptoms were milder than in the classical presentation. Either they had a delayed starting date (patients 6, 7, and 8) or outputs were less considerable than in classic MVID. Parenteral nutrition could even be stopped in 3 patients. To our knowledge, these are the third and fourth spontaneous cures described to date (11,23).

Three patients had a cholestasis with low GGT levels whose evolution was fluctuant with medical treatment. One still had severe pruritus. In a previous study, cholestasis was described in 25% of the patients, before or even after isolated small bowel transplantation (15). It is known that myosin 5b is important for hepatocyte polarization (38). It is therefore possible that a dysfunction of myosin 5b leads to a defect of hepatocyte apical transporters (39).

All but 2 patients had MYO5B mutations. For the remaining 2 patients, the genetic defect remains to be identified. The exome sequencing strategy used here did not allow discarding genetic changes such as exon deletions or mutations within the MYO5B promotor region; however, immunohistochemical analyses of myosin 5b showed a normal signal, and thus did not argue for MYO5B gene abnormalities. For these patients, it should be more interesting to study alternative genes involved in the transport of apical proteins such as Rab8a, Rab11a, or FIP5. Because mutations in syntaxine 3 have been reported for 2 patients with MIVD, this gene should also be tested (40).

In patients with mutations, the functional impact of the mutations was not further examined with functional studies; however, among the mutations identified here, one was present in 2 families (patients 1, 7, and 8) and another one was already reported in a typical Turkish patient (31). More important, mutated patients carried 2 mutations as expected for a Mendelian recessive disorder. Thus, we conclude that patients’ mutations likely contribute to their histological and clinical findings.

MIVD is a rare pathology, with well-recognized clinical and histological aspects in its classic form. Most of the patients exhibit MYO5B mutations. This study suggests to extend the clinical spectrum of MVID to patients with less severe diarrhea and/or associated diseases.

Back to Top | Article Outline

Acknowledgments

The authors thank Alain Grodet for technical support.

Back to Top | Article Outline

REFERENCES

1. Guarino A, Spagnuolo MI, Russo S, et al. Etiology and risk factors of severe and protracted diarrhea. J Pediatr Gastroenterol Nutr 1995; 20:173–178.
2. Ventura A, Dragovich D. Intractable diarrhoea in infancy in the 1990s: a survey in Italy. Eur J Pediatr 1995; 154:522–525.
3. Beck NS, Kang IS, Suh YL. Protracted diarrhea: results of the five-year survey in a tertiary hospital in Korea. J Korean Med Sci 2001; 16:736–741.
4. Davidson GP, Cutz E, Hamilton JR, et al. Familial enteropathy: a syndrome of protracted diarrhea from birth, failure to thrive, and hypoplastic villus atrophy. Gastroenterology 1978; 75:783–790.
5. Roggero P, Mazzola C, Fava G, et al. Intestinal microvillous atrophy and transient neuronal dysplasia. Transplant Proc 1997; 29:1868–1869.
6. Kennea N, Norbury R, Anderson G, et al. Congenital microvillous inclusion disease presenting as antenatal bowel obstruction. Ultrasound Obstet Gynecol 2001; 17:172–174.
7. Chen CP, Chiang MC, Wang TH, et al. Microvillus inclusion disease: prenatal ultrasound findings, molecular diagnosis and genetic counseling of congenital diarrhea. Taiwan J Obstet Gynecol 2010; 49:487–494.
8. Levental M, Pretorius DH, Scioscia AL, et al. Prenatal detection of echogenic bowel in a fetus with familial microvillous atrophy. J Ultrasound Med 2002; 21:351–354.
9. Phillips AD, Schmitz J. Familial microvillous atrophy: a clinicopathological survey of 23 cases. J Pediatr Gastroenterol Nutr 1992; 14:380–396.
10. Ruemmele FM, Schmitz J, Goulet O. Microvillous inclusion disease (microvillous atrophy). Orphanet J Rare Dis 2006; 1:22.
11. Martinez MA, Egea AS, Lopez JM, et al. Intestinal microvillous atrophy in a patient with Down syndrome and aganglionic megacolon. Ultrastruct Pathol 2002; 26:41–45.
12. Raafat F, Green NJ, Nathavitharana KA, et al. Intestinal microvillous dystrophy: a variant of microvillous inclusion disease or a new entity? Hum Pathol 1994; 25:1243–1248.
13. Gathungu GN, Pashankar DS, Sarita-Reyes CD, et al. Microvillus inclusion disease associated with coarctation of the aorta and bicuspid aortic valve. J Clin Gastroenterol 2008; 42:400–403.
14. Loverdos I, GM, Lacaille F, et al. Severe intrahepatic cholestasis in microvillous inclusion disease. J Pediatr Gastroenterol Nutr 2009; 48: (E23).
15. Halac U, Lacaille F, Joly F, et al. Microvillous inclusion disease: how to improve the prognosis of a severe congenital enterocyte disorder. J Pediatr Gastroenterol Nutr 2011; 52:460–465.
16. Heinz-Erian P, Schmidt H, Le Merrer M, et al. Congenital microvillus atrophy in a girl with autosomal dominant hypochondroplasia. J Pediatr Gastroenterol Nutr 1999; 28:203–205.
17. Phillips AD, Jenkins P, Raafat F, et al. Congenital microvillous atrophy: specific diagnostic features. Arch Dis Child 1985; 60:135–140.
18. Walker-Smith JA, Phillips AD, Walford N, et al. Intravenous epidermal growth factor/urogastrone increases small-intestinal cell proliferation in congenital microvillous atrophy. Lancet 1985; 2:1239–1240.
19. Drumm B, Cutz E, Tomkins KB, et al. Urogastrone/epidermal growth factor in treatment of congenital microvillous atrophy. Lancet 1988; 1:111–112.
20. Pohl JF, Shub MD, Trevelline EE, et al. A cluster of microvillous inclusion disease in the Navajo population. J Pediatr 1999; 134:103–106.
21. Ruemmele FM, Jan D, Lacaille F, et al. New perspectives for children with microvillous inclusion disease: early small bowel transplantation. Transplantation 2004; 77:1024–1028.
22. Herzog D, Atkison P, Grant D, et al. Combined bowel-liver transplantation in an infant with microvillous inclusion disease. J Pediatr Gastroenterol Nutr 1996; 22:405–408.
23. Croft NM, Howatson AG, Ling SC, et al. Microvillous inclusion disease: an evolving condition. J Pediatr Gastroenterol Nutr 2000; 31:185–189.
24. Al-Daraji WI, Zelger B, Hussein MR. Microvillous inclusion disease: a clinicopathologic study of 17 cases from the UK. Ultrastruct Pathol 2010; 34:327–332.
25. Schofield DE, Agostini RM Jr, Yunis EJ. Gastrointestinal microvillus inclusion disease. Am J Clin Pathol 1992; 98:119–124.
26. Groisman GM, Amar M, Livne E. CD10: a valuable tool for the light microscopic diagnosis of microvillous inclusion disease (familial microvillous atrophy). Am J Surg Pathol 2002; 26:902–907.
27. Groisman GM, Ben-Izhak O, Schwersenz A, et al. The value of polyclonal carcinoembryonic antigen immunostaining in the diagnosis of microvillous inclusion disease. Hum Pathol 1993; 24:1232–1237.
28. Iancu TC, Mahajnah M, Manov I, et al. Microvillous inclusion disease: ultrastructural variability. Ultrastruct Pathol 2007; 31:173–188.
29. Phillips AD, Szafranski M, Man LY, et al. Periodic acid-Schiff staining abnormality in microvillous atrophy: photometric and ultrastructural studies. J Pediatr Gastroenterol Nutr 2000; 30:34–42.
30. Nathavitharana KA, Green NJ, Raafat F, et al. Siblings with microvillous inclusion disease. Arch Dis Child 1994; 71:71–73.
31. Müller T, Hess MW, Schiefermeier N, et al. MYO5B mutations cause microvillus inclusion disease and disrupt epithelial cell polarity. Nat Genet 2008; 40:1163–1165.
32. Ruemmele FM, Muller T, Schiefermeier N, et al. Loss-of-function of MYO5B is the main cause of microvillus inclusion disease: 15 novel mutations and a CaCo-2 RNAi cell model. Hum Mutat 2010; 31:544–551.
33. Szperl AM, Golachowska MR, Bruinenberg M, et al. Functional characterization of mutations in the myosin Vb gene associated with microvillus inclusion disease. J Pediatr Gastroenterol Nutr 2011; 52:307–313.
34. Erickson RP, Larson-Thome K, Valenzuela RK, et al. Navajo microvillous inclusion disease is due to a mutation in MYO5B. Am J Med Genet A 2008; 146A:3117–3119.
35. Phillips A, Fransen J, Hauri HP, et al. The constitutive exocytotic pathway in microvillous atrophy. J Pediatr Gastroenterol Nutr 1993; 17:239–246.
36. Phillips AD, Brown A, Hicks S, et al. Acetylated sialic acid residues and blood group antigens localise within the epithelium in microvillous atrophy indicating internal accumulation of the glycocalyx. Gut 2004; 53:1764–1771.
37. Roland JT, Bryant DM, Datta A, et al. Rab GTPase-Myo5B complexes control membrane recycling and epithelial polarization. Proc Natl Acad Sci U S A 2011; 108:2789–2794.
38. Wakabayashi Y, Dutt P, Lippincott-Schwartz J, et al. Rab11a and myosin Vb are required for bile canalicular formation in WIF-B9 cells. Proc Natl Acad Sci U S A 2005; 102:15087–15092.
39. Girard M, Lacaille F, Verkarre V, et al. MYO5B and BSEP contribute to cholestatic liver disorder in microvillous inclusion disease. Hepatology 2014; 60:301–310.
40. Wiegerinck CL, Janecke AR, Schneeberger K, et al. 1. Loss of syntaxin 3 causes variant microvillus inclusion disease. Gastroenterology 2014; 147:65.e10–68.e10.
Keywords:

intractable diarrhea; microvillous atrophy; microvillous inclusion disease; myosin 5b

Supplemental Digital Content

Back to Top | Article Outline
© 2014 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology,